ReN001

Type: Product
Name: ReN001
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

ReNeuron Group plc : Posting of Annual Report & Notice of AGM

AIM: RENE ReNeuron Group plc("ReNeuron" or the "Company") Posting of Annual Report & Accounts and Notice of AGM Guildford, UK, 17 July 2014ReNeuron's AGM will be held at 10:00am on Tuesday 2 September 2014 at the offices of Covington & Burling LLP, 265 ... [Published Investegate - Jul 17 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

ReNeuron upbeat after "transformational" year

Stem cell specialist ReNeuron ( LON:RENE )says it's upbeat after what it called a 'transformational' year, as it posted results for the year to end March. A share placing in July raised £25.3mln bolstering the balance sheet and will fund key second ... [Published Proactiveinvestors United Kingdom RSS feed - Jun 18 2014]
First reported May 16 2014 - Updated May 16 2014 - 1 reports

This week: Shoe Zone sizing up IPO, Flowtech powering towards AIM, Conroy Gold reaffirming strong portfolio

BLUR trading update,CGNR wide mineralised zones,Flowtech Fluidpower intention to float on AIM,Marimedia intention to float on AIM,PEG AGM Statement,RENE new data,RXB first day of dealings on AIM,Shoe Zone intention to float on AIM,XLM preliminary results,C21 ... [Published Proactiveinvestors United Kingdom RSS feed - May 16 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 1 reports

Proactive news summary: Leni Gas & Oil, Mediterranean Oil & Gas, ReNeuron, San Leon Energy, Baobab Resources

Long-suffering shareholders in Mediterranean Oil & Gas ( LON:MOG ) were finally put out of their misery as the High Court ruled in its favour, leaving Leni Gas & Oil ( LON:LGO ) investors with a sour taste. LGO took MOG to court after selling it ... [Published Proactiveinvestors United Kingdom RSS feed - Mar 27 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 2 reports

UK Clinical Trial Approvals

27 March 2014AIM: RENEReNeuron receives UK regulatory approvals for Phase II clinical trial in stroke and Phase I clinical trial in critical limb ischaemiaGuildford, UK, 27 March 2014:   ReNeuron Group  plc (the "Company") (AIM: RENE.L), a leading UK-based ... [Published TrustNet - Mar 27 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Market movers: Power companies, Randgold Resources, Reneuron, Baobab, Sunrise

Miners and power companies were weighing heavy on Footsie in the first hour’s trading.  The blue chip index was trading 19 points lower at 6,585, while the flagship Aim index dipped 18 to 1,800. Power companies were making the headlines again as Britain's ... [Published Proactiveinvestors United Kingdom RSS feed - Mar 27 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

Support for Early Access to Medicines Scheme

14 March 2014 AIM: RENEReNeuron welcomes launch of UK Government Early Access to Medicines SchemeGuildford, UK, 14 March 2014:   ReNeuron Group   plc (the "Company") (AIM: RENE.L), a leading UK-based stem cell therapy company, welcomes today's announcement ... [Published TrustNet - Mar 14 2014]

Quotes

"In both cases, and earlier-than-planned, we have gained regulatory approval to use a second-generation cryopreserved variant of our lead CTX stem cell line, providing the potential for significant commercial and competitive advantages for our business."
...Rex Bionics " marketed products: REX Rehab and REX Personal, can be used by people with complete spinal cord injury, but also by a much broader potential customer base, including people with multiple sclerosis and muscular dystrophy. "
"We are delighted to have received these concurrent clinical trial approvals for our stroke and critical limb ischaemia programmes.  It is especially pleasing to have been given approval to use our second-generation CTXcryo cells in both of these new clinical trials. The fact that this new product variant is being deployed clinically much earlier than we had planned is illustrative of ReNeuron's ability, in collaboration with its various partners, to successfully innovate and sustain its commercial and competitive edge."
Chief executive Michael Hunt said: "We are delighted to have received these concurrent clinical trial approvals for our stroke and critical limb ischaemia programmes."

More Content

All (10) | News (10) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
ReNeuron Group plc : Posting of Annual Report &... [Published Investegate - Jul 17 2014]
ReNeuron upbeat after "transformational" year [Published Proactiveinvestors United Kingdom RSS feed - Jun 18 2014]
This week: Shoe Zone sizing up IPO, Flowtech po... [Published Proactiveinvestors United Kingdom RSS feed - May 16 2014]
Proactive news summary: Leni Gas & Oil, Mediter... [Published Proactiveinvestors United Kingdom RSS feed - Mar 27 2014]
Market movers: Power companies, Randgold Resour... [Published Proactiveinvestors United Kingdom RSS feed - Mar 27 2014]
UK Clinical Trial Approvals [Published TrustNet - Mar 27 2014]
Pace of progress quickens at ReNeuron as it get... [Published Proactiveinvestors United Kingdom RSS feed - Mar 27 2014]
Support for Early Access to Medicines Scheme [Published TrustNet - Mar 14 2014]
Interim Results [Published TrustNet - Dec 02 2013]
Notification of Interim Results [Published TrustNet - Nov 19 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.